<DOC>
	<DOCNO>NCT01626651</DOCNO>
	<brief_summary>The purpose study assess potential effect ketoconazole pharmacokinetics ibrutinib healthy participant .</brief_summary>
	<brief_title>A Study Assess Effect Ketoconazole Pharmacokinetics Ibrutinib Healthy Participants</brief_title>
	<detailed_description>This single-center , open-label ( people know identity intervention ) , sequential design study healthy men . All participant receive ibrutinib Day 1 ibrutinib combination ketoconazole Day 7 . Food restrict even dose 4 hour dose Days 1 7 . Following overnight fast , ketoconazole give Days 4 6 , 1 hour prior ibrutinib dose Day 7 , Days 8 9 . All ibrutinib ketoconazole dos administer water . The participant leave study center Day 10 .</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Body mass index ( BMI ) 18 30 kg/m2 , body weight less 50 kg Blood pressure 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic Nonsmoker Must agree use adequate contraception method study minimally 3 month last dose ibrutinib , donate sperm study 3 month receive last dose study drug Signed inform consent document History current clinically significant medical illness Clinically significant abnormal physical examination , vital sign electrocardiogram ( ECG ) Clinically significant abnormal value laboratorial test Use prescription nonprescription medication , except acetaminophen , within 3 day first dose study drug schedule History , reason believe participant history drug alcohol abuse within past 2 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Ketoconazole</keyword>
	<keyword>Ibrutinib</keyword>
</DOC>